Resources for each step of the treatment journey with AUSTEDO

Teva is committed to supporting you, your tardive dyskinesia (TD) patients, and their carepartners.

Downloadable resources for prescribers

Impact of TD Questionnaire

Use this questionnaire to help identify and assess the impact of TD when evaluating patients.

Prescription and Service Request Form (PSRF)

Fill out this form to enroll your patient in Teva’s Shared Solutions®.

Appeals Letter Template

Use this template to write an appeals letter, which payers may need to appeal a denial of coverage for AUSTEDO.

Letter of Medical Necessity Template

Use this template to write a letter to establish medical necessity, which payers may require for treatment with AUSTEDO.


Downloadable resources for your patients with TD

Your Daily Treatment and Activity Log

A useful resource to help initiate conversations with patients during their treatment. Patients and their carepartners can use this tracking tool to record when they take AUSTEDO, as well as any changes in their TD.

Patient Brochure for AUSTEDO

This brochure provides answers to important questions your patients with TD and their carepartners may have when starting treatment with AUSTEDO.

Purple video icon.

Videos to help you support your patients with TD

play button

Mechanism of Action

VMAT2 inhibition can help regulate dopamine function.1

play button

TD Movements Over Time

See the treatment journey of Charlene, a patient taking AUSTEDO, and find information on titration and the effects on symptom control.


Faces of TD: Hypothetical patient case studies presented by specialists

play button

Brian, a patient with bipolar disorder, who has had his routine disrupted by TD.

play button

Lisa, a patient with schizophrenia, whose movements are starting to impact her time with her family.

play button

Patricia, a patient with major depressive disorder, who is also taking an antihypertensive.


TD Talks: Informative videos on TD evaluation and treatment

play button

Dr. Rajeev Kumar talks about AUSTEDO for the treatment of TD.

play button

Dr. Rakesh Jain discusses drug metabolism as a crucial consideration for TD treatment.

play button

Amber Hoberg, PMHNP-BC, discusses the importance of assessing and managing TD.


Demystifying EPS: TD Is Distinct—a 3-part series on the importance of differential diagnosis

play button

Chapter 1: Considering the landscape of antipsychotic usage.

play button

Chapter 2: Operating mechanisms of TD and drug-induced parkinsonism (DIP).

play button

Chapter 3: Differential diagnosis of TD.


TD virtual assessments, demonstrated by Dr. Arvinder Walia

play button

A long virtual assessment, with full view of the patient’s body.

play button

A short virtual assessment, without full view of the patient’s body.

EPS, extrapyramidal symptoms; VMAT2, vesicular monoamine transporter 2.

REFERENCE: 1. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238. doi:10.2147/DDDT.S133205